Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Luxturna
Pharma
Novartis targets Xiidra in eye disease asset sale: Bloomberg
Novartis has tapped an adviser to start selling some ophthalmology assets, Bloomberg reports. But not all Novartis eye drugs are up for sale.
Angus Liu
Mar 14, 2023 10:22am
2022 forecast: Cell, gene therapy makers have high hopes
Dec 22, 2021 3:00am
Novartis, Spark gene therapies score top-notch Cigna coverage
Sep 6, 2019 11:20am
NICE hands Novartis a gene therapy win with Luxturna backing
Sep 4, 2019 10:59am
The most expensive U.S. meds, featuring new gene therapies
Jun 13, 2019 11:00am
Post-Alcon Novartis eyes M&A in ophthalmic digital therapeutics
Apr 9, 2019 1:00pm
